Sensing amyloid-β aggregation using luminescent dipyridophenazine ruthenium(II) complexes
Nathan P Cook1, Veronica Torres, Disha Jain
1Department of Chemistry, Rice University, 6100 South Main Street, Houston, Texas 77005, USA.
Journal of the American Chemical Society
|July 1, 2011
Summary
A novel ruthenium complex detects amyloid-β (Aβ) fibril formation, crucial for Alzheimer's disease research. Its luminescence activates upon Aβ aggregation, enabling sensitive monitoring.
Area of Science:
- Biochemistry
- Materials Science
- Neuroscience
Background:
- Amyloid-β (Aβ) peptide aggregation is linked to Alzheimer's disease pathogenesis.
- Monitoring Aβ fibrillization is essential for understanding and diagnosing Alzheimer's disease.
Purpose of the Study:
- To introduce a luminescent ruthenium(II) complex for monitoring Aβ fibrillization.
- To evaluate the complex's efficacy in detecting Aβ aggregates.
Main Methods:
- Utilized a luminescent dipyridophenazine ruthenium(II) complex.
- Investigated the complex's photoluminescence in the presence of Aβ monomers and fibrils.
- Employed time-gating technology for detection in fluorescent media.
Main Results:
- The ruthenium complex showed no photoluminescence with monomeric Aβ but strong luminescence with Aβ fibrils.
- The complex possesses a large Stokes shift (180 nm) and a long luminescence lifetime.
- Successful detection of fibrillar proteins in highly fluorescent backgrounds was demonstrated.
Conclusions:
- Dipyridophenazine ruthenium(II) complexes are effective tools for monitoring protein fibrillization.
- This method offers advantages for detecting amyloid-β aggregates in complex biological environments.
- The developed complex shows promise for Alzheimer's disease diagnostics and research.
